Abstract:Gliomas, a type of primary brain tumor, have emerged as a threat to global mortality due to their high heterogeneity and mortality. A low-grade glioma (LGG), although less aggressive compared with glioblastoma, still exhibits high recurrence and malignant progression. Ubiquitination is one of the most important posttranslational modifications that contribute to carcinogenesis and cancer recurrence. E3-related genes (E3RGs) play essential roles in the process of ubiquitination. Yet, the biological function and clinical significance of E3RGs in LGGs need further exploration. In this study, differentially expressed genes (DEGs) were screened by three differential expression analyses of LGG samples from The Cancer Genome Atlas (TCGA) database. DEGs with prognostic significance were selected by the univariate Cox regression analysis and log-rank statistical test. The LASSO-COX method was performed to identify an E3-related prognostic signature consisting of seven genes AURKA, PCGF2, MAP3K1, TRIM34, PRKN, TLE3, and TRIM17. The Chinese Glioma Genome Atlas (CGGA) dataset was used as the validation cohort. Kaplan-Meier survival analysis showed that LGG patients in the low-risk group had significantly higher overall survival time than those in the high-risk group in both TCGA and CGGA cohorts. Furthermore, multivariate Cox regression analysis revealed that the E3RG signature could be used as an independent prognostic factor. A nomogram based on the E3RG signature was then established and provided the prediction of the 1-, 3-, and 5-year survival probability of patients with LGGs. Moreover, DEGs were analyzed based on the risk signature, on which function analyses were performed. GO and KEGG analyses uncovered gene enrichment in extracellular matrix-related functions and immune-related biological processes in the high-risk group. GSEA revealed high enrichment in pathways that promote tumorigenesis and progression in the high-risk group. Furthermore, ESTIMATE algorithm analysis showed a significant difference in immune and stroma activity between high- and low-risk groups. Positive correlations between the risk signature and the tumor microenvironment immune cell infiltration and immune checkpoint molecules were also observed, implying that patients with the high-risk score may have better responses to immunotherapy. Overall, our findings might provide potential diagnostic and prognostic markers for LGG patients and offer meaningful insight for individualized treatment.

Elevated GAS2L3 Expression Correlates with Poor Prognosis in Patients with Glioma: A Study Based on Bioinformatics and Immunohistochemical Analysis

High expression of COPB2 predicts adverse outcomes: A potential therapeutic target for glioma.

Elevated SLC3A2 associated with poor prognosis and enhanced malignancy in gliomas

Prognostic Value and Biological Function of Galectins in Malignant Glioma.

Dysregulation of LINC00324 promotes poor prognosis in patients with glioma

Comprehensive Bioinformatics Analysis of Gasdermin Family of Glioma

Influence of S1PR3 expression on the glioma microenvironment and prognostic significance in low-grade gliomas

Molecular and Clinical Characterization of a Novel Prognostic and Immunologic Biomarker GPSM3 in Low-Grade Gliomas

Comprehensive Characterization of a Novel E3-Related Gene Signature with Implications in Prognosis and Immunotherapy of Low-Grade Gliomas.

A novel Golgi related genes based correlation prognostic index can better predict the prognosis of glioma and responses to immunotherapy

Prognostic value of γ‐aminobutyric acidergic synapse-associated signature for lower-grade gliomas

High Levels of HIST1H2BK in Low-Grade Glioma Predicts Poor Prognosis: A Study Using CGGA and TCGA Data

S100A gene family: immune-related prognostic biomarkers and therapeutic targets for low-grade glioma

Overexpression of Golgi Phosphoprotein-3 (GOLPH3) in Glioblastoma Multiforme is Associated with Worse Prognosis

CSF3R as a potential prognostic biomarker and immunotherapy target in glioma

SLC10A3 Is a Prognostic Biomarker and Involved in Immune Infiltration and Programmed Cell Death in Lower Grade Glioma

ITGA1 Promotes Glioma Cell Proliferation and Affects Immune Cell Infiltration in Low‐Grade Glioma

PBX3 as a biomarker for the early diagnosis and prediction of prognosis of glioma

Identification of IGF2BP3 As an Adverse Prognostic Biomarker of Gliomas

A glycosylation-related gene signature predicts prognosis, immune microenvironment infiltration, and drug sensitivity in glioma

Pyroptosis-Related Gene Signature Predicts Prognosis and Indicates Immune Microenvironment Infiltration in Glioma